President Donald Trump announced on Thursday (November 6) that his administration has reached an agreement with drugmakers Novo Nordisk and Eli Lilly to reduce the cost of their popular GLP-1 weight loss drugs , Wegovy and Zepbound. The deal aims to make these medications more affordable for millions of Americans struggling with obesity.

Under the agreement, the monthly out-of-pocket cost for these drugs could range from $50 to $350, depending on dosage and insurance coverage. Currently, these drugs can cost over $1,000 per month. The deal also includes plans to offer these treatments directly to consumers at a discount through a new website, TrumpRx.gov, launching in January.

The agreement is part of President Trump's "most favored nation" initiative, which seeks to align U.S. dru

See Full Page